Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) for Advanced-Stage Hodgkin's Disease: CALGB 8856

REFERENCES

• Hryniuk W. M. Average Relative Dose Intensity and the Impact on Design of Clinical Trials. Semin. Oncol 1987; 14: 65–74
   PubMed Web of Science ®Google Scholar
• Wood W. C., Budman D. R., Korzun A. H., et al. Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. N. Engl. J. Med. 1994; 330: 1253–1259
   Google Scholar
• DeVita V. T., Hubbard S. M., Longo D. L. The Chemotherapy of Lymphomas: Looking Back, Moving Forward—the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1987; 47: 5810–5824
   PubMed Web of Science ®Google Scholar
• Crump M., Smith A. M., Brandwein J., et al. High-Dose Etoposide and Melphalan, and Autologous Bone Marrow Transplantation for Patients with Advanced Hodgkin's Disease: Importance of Disease Status at Transplant. J. Clin. Oncol. 1993; 11: 704–711
   PubMed Web of Science ®Google Scholar
• Chopra R., McMillan A. K., Linch D. C., at al. The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Taylor P. R.A., Jackson G. H., Lennard A. L., et al. Autologous Transplantation in Poor Risk Hodgkin's Disease Using High Dose Melphalan/Etoposide Conditioning with Non-Cryopreserved Marrow Rescue. Br. J. Cancer 1993; 67: 383–387
   PubMed Web of Science ®Google Scholar
• Canellos G. P., Anderson J. R., Propert K. J.et al. Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD. N. Engl. J.Med. 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Miller T. P., Jones S. E., Rainey J. M. Cyclophosphamide,Doxorubicin, Vincristine, and Prednisone (CHOP)in Patients with Advanced Hodgkin's Disease: A Southwest Oncology Group Phase II Study. Cancer Treat. Rep. 1983; 67: 739–740
   PubMedGoogle Scholar
• Gaynor E. R., Golomb H. M. Salvage Chemotherapy of Hodgkin's and Non-Hodgkin's Lymphoma. Etoposide: Current Status and New Developments, B. F. Issell, F. M. Muggia, S. M. Carter. Academic, Orlando, FL 1984; 273–292
   Google Scholar
• Schulman P., McCarroll K., Cooper M. R., et al. Phase II Study of MOPLACE Chemotherapy for Patients with Previously Treated Hodgkin's Disease: A CALGB Study. Med. Pediatr. Oncol. 1990; 18: 482–486
   PubMedGoogle Scholar
• Kirshner J. J., Anderson J. R., Parker B., et al. Etoposide in Combination as First-Line Chemotherapy for Advanced Hodgkin Disease. Cancer 1993; 71: 1852–1856
   PubMed Web of Science ®Google Scholar
• Longo D. L., Young R. C., Wesley M., et al. Twenty Years of MOPP Therapy for Hodgkin's Disease. J. Clin. Oncol. 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• DeVita V. T., Hubbard S. M. Hodgkin's Disease. N.Engl. J. Med. 1993; 328: 560–565
   PubMed Web of Science ®Google Scholar
• Bonadonnaxt G., Zucali R., Monfardini S., et al. Combination Chemotherapy of Hodgkin's Disease with Adriamycin, Bleomycin, Vinblastine, and Imidazole Carboxamide Versus MOPP. Cancer 1975; 36: 252–259
   PubMed Web of Science ®Google Scholar
• Goldie J. H., Coldman A. J. A Mathematical Model for Relating the Drug Sensitivity of Tumors to their Spontaneous Mutation Rate. Cancer Treat. Rep. 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Glick J., Tsiatis A., Schilsky R., et al. for ECOG, CALGB, and SWOG. A Randomized Phase III Trial of MOPP/ABV Hybrid vs. Sequential MOPP-ABVD in Advanced Hodgkin's Disease: Preliminary Results of the Intergroup Trial. Proc. Am. Soc. Clin. Oncol. 1991; 10: 271, abstract 941
   Google Scholar
• Duggan D., Petroni G., Johnson J., et al. for CALGB. MOPP/ABV Versus ABVD for Advanced Hodgkin's Disease—aPreliminary Report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc. Am. Soc. Clin. Oncol. 1997; 16: 12a, abstract 43
   Google Scholar
• Fabian C. J., Mansfield C. M., Dahlberg S., et al. Low-Dose Involved Field Radiation After Chemotherapy in Advanced Hodgkin Disease, a Southwest Oncology Group Randomized Study. Ann. Int. Med. 1994; 120: 903–912
   PubMed Web of Science ®Google Scholar
• Vose J. M., Bierman P. J., Anderson J. R., et al. CHLVPP Chemotherapy with Involved-Field Irradiation for Hodgkin's Disease: Favorable Results with Acceptable Toxicity. J. Clin. Oncol. 1991; 9: 1421–1425
   PubMed Web of Science ®Google Scholar
• Loeffler M., Diehl V., Pfreundschuh M., et al. Dose- Response Relationship of Complementary Radiotherapy Following Four Cycles of Combination Chemotherapy in Intermediate-Stage Hodgkin's Disease. J. Clin. Oncol. 1997; 15: 2275–2287
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Quirt I. C., Skillings J. R., et al. Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma. N. Engl. J. Med. 1993; 329: 1770–1776
   PubMed Web of Science ®Google Scholar
• Shipp M, et al. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. N. Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hasenclever D., Diehl V. A Prognostic Scorefor Advanced Hodgkin's Disease. N. Engl. J. Med. 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Proctor S. J., Taylor P., Mackie M. J., et al. A Numerical Prognostic Index for Clinical Use in Identification of Poor-Risk Patients with Hodgkin's Disease at Diagnosis. Leuk. Lymphoma 1992; 7(suppl): 17–20
   PubMed Web of Science ®Google Scholar
• Parker B. A., Petroni G. R., Canellos G. P., et al. Dose-Intensified Cyclophosphamide (C) and Etoposide (E) in CHOP Plus E (CHOPE) Therapy of Diffuse Lymphomas (IWF E-H), CALGB 8852. Blood 1994; 84: 384a, abstrac 1522
   PubMed Web of Science ®Google Scholar
• Bower M., Parry P., Gibbons B., et al. Human Trithorax Gene Rearrangements in Therapy-Related Acute Leukemia After Etoposide Treatment. Leukemia 1994; 8: 226–229
   PubMed Web of Science ®Google Scholar
• Nichols C. R., Breeden E. S., Loehrer P. Secondary Leukemia Associated with a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols. J. Natl. Cancer Inst. 1993; 85: 36–41
   PubMed Web of Science ®Google Scholar
• Bajorin D. F., Motzer R. J., Rodriquez E., et al. Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated with Etoposide-Containing Chemotherapy. J. Natl. Cancer Inst. 1993; 85: 60–64
   PubMed Web of Science ®Google Scholar
• Haim N., Epelbaum R., Ben-Shahar M., et al. Full Dose Vincristine (Without 2-mg Dose Limit) in the Treatment of Lymphomas. Cancer 1994; 73: 2515–2519
   PubMed Web of Science ®Google Scholar
• Bonfante V., Santoro A., Viviani S., et al. ABVD in the Treatment of Hodgkin's Disease. Semin. Oncol. 1992; 19: 38–45
   PubMedGoogle Scholar
• Viviani S., Bonadonna G., Santoro A., et al. Alternating Versus Hybrid MOPP and ABVD Combinations in Advanced Hodgkin's Disease: Ten-Year Results. J. Clin. Oncol. 1996; 14: 1421–1430
   PubMed Web of Science ®Google Scholar
• Diehl V., Franklin J., Hasenclever D., et al. BEACOPP, a New Dose-Escalated and Accelerated Regimen, Is at Least as Effective as COPP/ABVD in Patients with Advanced-Stage Hodgkin's Lymphoma: Interim Report from a Trial of the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 1998; 16: 3810–3821
   PubMed Web of Science ®Google Scholar
• Diehl V., Franklin J., Hasenclever D., et al. BEACOPP: A New Regimen for Advanced Hodgkin's Disease. Ann. Oncol. 1998; 9 (suppl 5): 67–72
   Web of Science ®Google Scholar
• Radford J. A., Crowther D., Rohatiner A. Z.S., et al. Results of a Randomized Trial Comparing MVPP Chemotherapy with a Hybrid Regimen, ChlVPP/EVA, in the Initial Treatment of Hodgkin's Disease. J. Clin. Oncol 1995; 13: 2379–2385
   PubMed Web of Science ®Google Scholar
• Bartlett N. L., Rosenberg S. A., Hoppe R. T., et al. Brief Chemotherapy, Stanford V, and Adjuvant Radiotherapy for Bulky or Advanced-Stage Hodgkin's Disease: A Preliminary Report. J. Clin. Oncol 1995; 13: 1080–1088
   PubMed Web of Science ®Google Scholar
• Canellos G. P., Petroni G. R., Barcos M., et al. Etoposide, Vinblastine, and Doxorubicin: An Active Regimen for the Treatmentof Hodgkin's Disease in Relapse Following MOPP. J. Clin. Oncol 1995; 13: 2005–2011
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Bryant G., Bates S., et al. EPOCH Chemotherapy: Toxicity and Efficacy in Relapsed and Refractory Non-Hodgkin's Lymphomas. J. Clin. Oncol 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Bryant G., Wittes R., et al. EPOCH Chemotherapy (CT) Is Effective in Relapsed and Refractory Hodgkin's Disease (HD). Proc. Am. Soc. Clin. Oncol 1995; 14: 391, abstract 1224
   Google Scholar
• Carrion J. R., Garcia Arroyo F. R., Salinas P. Infusional Chemotherapy (EPOCH) in Patientswith Refractory orRelapsed Lymphoma. Am. J.Clin. Oncol 1995; 18: 44–46
   PubMed Web of Science ®Google Scholar
• Viviani S., Bonadonna G., Santoro A., et al. Alternating Versus Hybrid MOPP-ABVD in Hodgkin's Disease: The Milan Experience. Ann. Oncol 1991; 2: 55–62
   PubMed Web of Science ®Google Scholar
• Connors J. M., Klimo P., Adams G., et al. Treatment of Advanced Hodgkin's Disease with Chemotherapy— Comparisonof MOPP/ABV Hybrid Regimen with Alternating Courses of MOPP and ABVD: A Report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol 1997; 15: 1638–1645
   PubMed Web of Science ®Google Scholar